Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Guardant Health reported Q1 2026 revenue of $301.7 million, up 48% year-over-year, fueled by strong performance in both Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to $1.30 billion to $1.32 billion, representing growth of 32% to 34%, up from the prior range of $1.25 billion to $1.28 billion.
Key figures
- Revenue
- 301700000
- Guidance
- FY2026 revenue $1.30B-$1.32B, raised from $1.25B-$1.28B
- Revenue Yoy
- 48%
- Gross margin
- 65%
- Gross profit
- 196700000
- Screening tests
- 44000
- Oncology revenue
- 205000000
- Biopharma revenue
- 53000000
- Screening revenue
- 41600000
- Oncology revenue yoy
- 36%
- Oncology test volume
- 86000
- Non gaap gross margin
- 66%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.